FDA approves Revolution Medicines pancreatic cancer drug
Revolution Medicines received FDA approval on August 26, 2026, for daraxonrasib (Rasonque), a once-daily pill that blocks RAS protein variants driving pancreatic cancer growth.
Revolution Medicines received FDA approval on August 26, 2026, for daraxonrasib (Rasonque), a once-daily pill that blocks RAS protein variants driving pancreatic cancer growth.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug Reuters
The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.